In our lab, we have detected amplification-related overexpression of the RUNX2 gene in a subset of osteosarcoma tumours and identified a correlation between high RUNX2 mRNA overexpression and poor tumour response to chemotherapy based on the percentage of tumour necrosis following treatment [23]. Here, RUNX2 is linked to neoplasm.